A: Pleural neoplasm | Obs | RR (95% CI) |
Duration of exposure (years) | ||
<1 | 4 | 0.80 (0.25 to 2.53) |
1–4 | 10 | 0.76 (0.34 to 1.73) |
5–9 | 16 | 1.04 (0.53 to 2.01)) |
10–19 | 28 | 1 (ref) (–) |
20–29 | 53 | 1.46 (0.86 to 2.45) |
30 + | 28 | 1.88 (0.93 to 3.83) |
Latency (years) | ||
<10 | 1 | 0.20 (0.02 to 1.64) |
10–19 | 8 | 0.61 (0.26 to 1.44) |
20–29 | 23 | 1 (ref) (–) |
30–39 | 48 | 1.44 (0.81 to 2.56) |
40–49 | 40 | 1.86 (0.90 to 3.84) |
50+ | 19 | 1.19 (0.43 to 3.31) |
Time since last exposure (years) | ||
<3 | 13 | 0.67 (0.32 to 1.40) |
3–15 | 55 | 1 (ref) (–) |
15–30 | 55 | 0.90 (0.54 to 1.49) |
>30 | 16 | 0.65 (0.26 to 1.63) |
Age at first exposure and period of first exposure were not statistically significant and were not retained in the model. | ||
B: Peritoneal neoplasm | Obs | RR (95% CI) |
Duration of exposure (years) | ||
<1 | 0 | 0 (–) |
1–4 | 1 | 0.15 (0.02 to 1.19) |
5–9 | 5 | 0.68 (0.23 to 1.98) |
10–19 | 13 | 1 (ref) (–) |
20–29 | 22 | 1.23 (0.62 to 2.46) |
30+ | 15 | 1.22 (0.54 to 2.76) |
Latency (years) | ||
<10 | 1 | 0.72 (0.07 to 7.34) |
10–19 | 0 | 0 (–) |
20–29 | 5 | 1(ref) (–) |
30–39 | 17 | 3.15 (1.09 to 9.12) |
40–49 | 15 | 5.31 (1.62 to 17.49) |
50+ | 18 | 11.54 (2.80 to 47.64) |
Time since last exposure, age at first exposure and period of first exposure were not statistically significant and were not retained in the model. | ||
C: Lung cancer | Obs | RR (95% CI) |
Time since last exposure (years) | ||
<3 | 21 | 0.38 (0.22 to 0.65) |
3–15 | 125 | 1 (ref) (–) |
15–30 | 89 | 0.70 (0.52 to 0.95) |
>30 | 23 | 0.56 (0.35 to 0.92) |
Latency (years) | ||
<10 | 2 | 0.16 (0.04 to 0.69) |
10–19 | 16 | 0.48 (0.27 to 0.85) |
20–29 | 54 | 1 (ref). (–) |
30–39 | 114 | 1.64 (1.17 to 2.31) |
40–49 | 50 | 1.31 (0.86 to 2.00) |
50+ | 22 | 1.06 (0.59 to 1.88) |
Gender | ||
Female | 12 | 1 (ref). (–) |
Male | 246 | 8.34 (4.63 to 15.11) |
Age at first exposure and duration of exposure were not statistically significant and were not retained in the model. |
All models are adjusted by age, gender and period of follow-up. Obs, observed.